Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention

被引:231
作者
Mehta, Rajendra H. [1 ]
Starr, Aijing Z. [1 ]
Lopes, Renato D. [1 ]
Hochman, Judith S. [2 ]
Widimsky, Petr [3 ]
Pieper, Karen S. [1 ]
Armstrong, Paul W. [4 ]
Granger, Christopher B. [1 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27715 USA
[2] NYU, Sch Med, New York, NY USA
[3] Kralovske Vinohrady Univ Hosp, Prague, Czech Republic
[4] Univ Alberta, Edmonton, AB, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 301卷 / 17期
关键词
ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR; PRIMARY ANGIOPLASTY; ARRHYTHMIA BURSTS; FLOW RESTORATION; THROMBOLYSIS; THERAPY; PEXELIZUMAB;
D O I
10.1001/jama.2009.600
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The incidence and timing of sustained ventricular tachycardia or fibrillation (VT/VF) and its impact on outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) are poorly understood. Objective To evaluate the association of sustained VT/VF and its timing on the outcomes of patients presenting for primary PCI-an aim not prespecified in the APEX AMI trial. Design, Setting, and Patients We studied 5745 STEMI patients presenting for primary PCI at 296 hospitals in 17 countries between July 13, 2004, and May 11, 2006, from the APEX AMI trial. We categorized them into 4 groups: no VT/VF; VT/VF any time; early VT/VF, before the end of cardiac catheterization; and late VT/VF, after the end of cardiac catheterization. Main Outcome Measure Ninety-day total mortality. Results VT/VF occurred in 329 STEMI patients (5.7%) presenting for primary PCI. The majority of these occurred before the end of catheterization (n=205, 64%), and 90% occurred within 48 hours of presentation with symptoms of STEMI. Clinical outcomes were worse in patients with vs those without VT/VF(90-day mortality, 23.2% vs 3.6%; adjusted HR, 3.63; 95% CI, 2.59-5.09), and outcomes were worse if the VT/VF occurred late instead of early (90-day mortality for early VT/VF, 17.2%[adjusted HR, 2.34; 95% CI, 1.44-3.80]; for late VT/VF, 33.3% [adjusted HR, 5.59; 95% CI, 3.71-8.43]; for no VT/VF, 3.6% [referent]). In multivariate analyses, factors associated with early VT/VF included pre-PCI thrombolysis in MI (TIMI) flow grade 0 (HR, 2.94; 95% CI, 1.93-4.47), inferior infarction (HR, 2.16; 95% CI, 1.58-2.93), total baseline ST deviation (HR, 1.39; 95% CI, 1.19-1.63), creatinine clearance (HR, 0.88; 95% CI, 0.83-0.94), Killip class greater than I (HR, 1.88; 95% CI, 1.29-2.76), baseline systolic blood pressure (HR, 0.92; 95% CI, 0.87-0.98), body weight (HR, 1.16; 95% CI, 1.04-1.29), and baseline heart rate greater than 70/min (HR, 1.10; 95% CI, 1.01-1.20) (c index, 0.75). Factors related to late VT/VF were systolic blood pressure (HR, 0.83; 95% CI, 0.76-0.91), ST resolution less than 70% (HR, 3.17; 95% CI, 1.60-6.28), baseline heart rate greater than 70/min (HR, 1.20; 95% CI, 1.08-1.33), total baseline ST deviation (HR, 1.43; 95% CI, 1.14-1.79), post-PCI TIMI flow less than grade 3(HR, 2.09; 95% CI, 1.24-3.52), pre-PCI TIMI flow grade 0(HR, 2.12; 95% CI, 1.20-3.75), and beta-blockers less than 24 hours (HR, 0.52; 95% CI, 0.32-0.85) (c index, 0.74). Conclusions In this study, occurrence of VT/VF before or after the end of cardiac catheterization in patients presenting for primary PCI was associated with increased 90-day mortality.
引用
收藏
页码:1779 / 1789
页数:11
相关论文
共 25 条
  • [1] [Anonymous], 1988, LANCET, V2, P349
  • [2] [Anonymous], 1986, LANCET, V1, P397
  • [3] [Anonymous], ACC AHA GUIDELINES M
  • [4] Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43
  • [5] Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
    Armstrong, PW
    Adams, PX
    Al-Khalidi, HR
    Hamm, C
    Holmes, D
    O'Neill, W
    Todaro, TG
    Vahanian, A
    Van de Werf, F
    Granger, CB
    [J]. AMERICAN HEART JOURNAL, 2005, 149 (03) : 402 - 407
  • [6] INCIDENCE AND SIGNIFICANCE OF VENTRICULAR-TACHYCARDIA AND FIBRILLATION IN THE ABSENCE OF HYPOTENSION OR HEART-FAILURE IN ACUTE MYOCARDIAL-INFARCTION TREATED WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR - RESULTS FROM THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) PHASE-II TRIAL
    BERGER, PB
    RUOCCO, NA
    RYAN, TJ
    FREDERICK, MM
    PODRID, PJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (07) : 1773 - 1779
  • [7] REPERFUSION ARRHYTHMIAS DURING CORONARY REPERFUSION THERAPY IN MAN - CLINICAL AND ANGIOGRAPHIC CORRELATIONS
    BUCKINGHAM, TA
    DEVINE, JE
    REDD, RM
    KENNEDY, HL
    [J]. CHEST, 1986, 90 (03) : 346 - 351
  • [8] Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-Segment elevation myocardial infarction
    Gibson, C. Michael
    Pride, Yuri B.
    Buros, Jacqueline L.
    Lord, Erin
    Shui, Amy
    Murphy, Sabina A.
    Pinto, Duane S.
    Zimetbaum, Peter J.
    Sabatine, Marc S.
    Cannon, Christopher P.
    Josephson, Mark E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (05) : 546 - 551
  • [9] HOLTER RECORDING OF VENTRICULAR ARRHYTHMIAS DURING INTRAVENOUS THROMBOLYSIS FOR ACUTE MYOCARDIAL-INFARCTION
    GRESSIN, V
    LOUVARD, Y
    PEZZANO, M
    LARDOUX, H
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (03) : 152 - 159
  • [10] HJALMARSON A, 1985, EUR HEART J, V6, P199